Quick Comparison
| 5-Amino-1MQ | Insulin | |
|---|---|---|
| Half-Life | 12-16 hours (limited pharmacokinetic data) | Rapid-acting (Humalog/Novolog): 1 hour | Regular (Humulin R): 1.5 hours | Long-acting (Lantus): 24 hours |
| Typical Dosage | Research: 50-100 mg oral once or twice daily. No FDA-approved dosing guidelines. No established cycling protocol. | Diabetes: individualized by physician based on blood glucose monitoring. Bodybuilding (extremely dangerous): 5-15 IU rapid-acting subcutaneous post-workout with mandatory high-carbohydrate and high-protein meal. Never to be used without blood glucose monitoring equipment immediately available. |
| Administration | Oral (capsule) | Subcutaneous injection. Timing varies by type (rapid, regular, long-acting). |
| Research Papers | 60 papers | 35 papers |
| Categories |
Mechanism of Action
5-Amino-1MQ
5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), a cytoplasmic enzyme that is significantly overexpressed in white adipose tissue of obese individuals. NNMT catalyzes the methylation of nicotinamide (a form of vitamin B3) using S-adenosyl methionine (SAM) as the methyl donor, producing 1-methylnicotinamide and S-adenosyl homocysteine. This reaction effectively depletes two critical metabolic cofactors — NAD+ precursors and SAM — from fat cells.
By inhibiting NNMT, 5-Amino-1MQ preserves the cellular pools of both nicotinamide (which feeds NAD+ biosynthesis via the salvage pathway) and SAM (the universal methyl donor required for hundreds of methylation reactions). Increased NAD+ availability activates sirtuin enzymes (particularly SIRT1 and SIRT3), which are master regulators of cellular metabolism — they deacetylate and activate PGC-1alpha (promoting mitochondrial biogenesis), enhance fatty acid oxidation, and suppress lipogenic gene expression. The net effect is that adipocytes shift from a fat-storing to a fat-burning metabolic state.
In preclinical models, NNMT inhibition reduced adipocyte size, decreased total body fat mass, and increased energy expenditure without affecting food intake — suggesting the weight loss mechanism is primarily metabolic rather than appetite-driven. Additionally, NNMT inhibition has shown improvements in insulin sensitivity and reductions in plasma cholesterol. However, all published efficacy data comes from cell culture and rodent studies; no human clinical trials have been completed, so the translational relevance remains uncertain.
Insulin
Insulin is a 51-amino-acid peptide hormone composed of two disulfide-linked chains (A-chain: 21 amino acids, B-chain: 30 amino acids), produced by pancreatic beta cells in the islets of Langerhans. It is the body's master metabolic regulator and the most potent anabolic hormone, controlling glucose homeostasis, energy storage, and cell growth across virtually all tissues.
Insulin binds to the insulin receptor (IR), a transmembrane receptor tyrosine kinase that exists as a preformed dimer. Binding induces conformational changes that activate the intracellular tyrosine kinase domains, which autophosphorylate and then phosphorylate insulin receptor substrate (IRS) proteins. This initiates two major downstream cascades. The PI3K/Akt pathway drives the metabolic effects: Akt phosphorylation promotes GLUT4 glucose transporter translocation to the cell membrane (increasing glucose uptake 10-20 fold in muscle and adipose tissue), activates glycogen synthase (storing glucose as glycogen), activates mTORC1 (stimulating protein synthesis through S6K1 and 4E-BP1), and inhibits hormone-sensitive lipase (suppressing lipolysis and fat breakdown). The Ras/MAPK pathway mediates the growth and mitogenic effects: promoting cell proliferation and gene expression.
In bodybuilding contexts, insulin's extreme anabolic potency stems from its simultaneous activation of multiple anabolic pathways and suppression of catabolic ones. It drives amino acids and glucose into muscle cells while blocking protein degradation and fat mobilization, creating a powerfully anabolic environment. When combined with GH (which mobilizes fatty acids) and IGF-1 (which promotes satellite cell differentiation), insulin creates synergistic muscle growth. However, this same potency makes insulin acutely dangerous — severe hypoglycemia from dosing errors can cause seizures, brain damage, coma, and death within hours. The narrow therapeutic window and life-threatening consequences of overdose make insulin the highest-risk compound used in bodybuilding.
Risks & Safety
5-Amino-1MQ
Common
stomach discomfort, nausea.
Serious
no completed human clinical trials, blocking NNMT could affect important cellular processes that are not yet fully understood.
Insulin
Common
low blood sugar (sweating, shaking, confusion, hunger), lumps at injection sites, weight gain.
Serious
severe low blood sugar can cause seizures, unconsciousness, brain damage, coma, and death from dosing errors or missed meals.
Rare
severe allergic reactions, dangerously low potassium.
Full Profiles
5-Amino-1MQ →
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Insulin →
The most powerful muscle-building hormone in your body — it drives nutrients (sugar, amino acids) directly into muscle cells. FDA-approved and essential for diabetes management. In bodybuilding, it's used for extreme muscle growth by forcing nutrients into muscles after workouts. However, it is the single most dangerous compound used in performance enhancement — a dosing error can cause seizures, brain damage, coma, or death within hours. The margin between an effective dose and a lethal dose is very small.